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Small for gestational age
Stunting
Wasting
a b s t r a c t
Background: Maternal influenza vaccination has increased birth weight in two randomized trials in South
Asia but the impact on infant growth is unknown.
Methods: A randomized placebo-controlled trial of year round maternal influenza immunization was
conducted in two annual cohorts in Sarlahi District, southern plains of Nepal, from April 2011 through
April 2014. Infants born to women enrolled in the trial had weight, length, and head circumference mea-
sured at birth and 6 months of age. The study was powered for the 3 primary trial outcomes but not for
stunting and wasting at 6 months of age.
Results: 3693 women received placebo or influenza vaccine between 17 and 34 weeks gestation, result-
ing in 3646 live births. About 72% of infants who survived had weight and length measurements between
150 and 210 days of age. Prevalence of stunting (<2 Z scores length-for-age) was 14.8% in the placebo
and 13.6% in the vaccine groups, respectively. Stunting < 3 Z scores was 3.2% versus 2.0% in placebo ver-
sus vaccine groups (RR: 0.64 (95% CI: 0.39, 1.04)). Wasting (< 2 Z scores weight for length) was 10.3%
versus 11.0% for placebo versus vaccine groups. Severe wasting (<3 Z scores weight for length) was 3.8%
for placebo versus 2.6% for vaccine (RR: 0.69 (95% CI: 0.44, 1.07)). The impact of flu vaccine on wasting
was greater in cohort 2 than in cohort 1, (RR: 0.66 (0.44, 0.99) for any wasting), and RR: 0.45 (0.19, 1.09)
for severe wasting. This corresponded to a larger impact on birth weight and a better vaccine match with
circulating viruses in cohort 2.
Conclusions: Although maternal immunization reduced low birth weight by 15%, only wasting at 6
months in the 2nd cohort was statistically significantly difference. However, the study was underpow-
ered to detect reductions of public health importance.
Conclusions: Trial Registration: Clinicaltrials.gov (NCT01034254).
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Influenza may cause severe disease in all ages of the population
worldwide, resulting in an estimated 19.2 million disability
adjusted life years in 2010 [1]. Women who contract influenza dur-
ing pregnancy have higher rates of morbidity and hospitalization
than the general population, and infants born to these women
are more likely to be preterm and of low birth weight (LBW,
https://doi.org/10.1016/j.vaccine.2017.09.095
0264-410X/ 2017 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Abbreviations: LBW, Low birth weight; WHO, World Health Organization; SGA,
small for gestational age; AGA, appropriate for gestational age; RR, risk ratio; CI,
confidence interval; BMI, body mass index.
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<2500 g) [2]. The impact of influenza disease during pregnancy and
birth outcomes has generally been documented in high-income
countries and most of the evidence for adverse effects on birth out-
comes is among women with severe or pandemic influenza [3].
Influenza vaccination is recommended for pregnant women by
the World Health Organization (WHO) to reduce maternal morbid-
ity during pregnancy and potentially to protect infants from influ-
enza early in life when morbidity is highest [4]. While this
recommendation covers all countries, most low- and middle-
income countries do not have policies or programs around mater-
nal influenza vaccination. In observational studies, women vacci-
nated in pregnancy have been shown to have higher birth weight
infants, reduced preterm births, LBW, and small-for-gestational
age (SGA) but these studies are subject to significant confounding
bias [5,6]. Recent large randomized controlled trials in Bangladesh,
Mali, South Africa and Nepal have examined the impact of mater-
nal influenza vaccination on maternal and infant influenza [7–12].
The Bangladesh and Nepal trials both showed impacts on birth
weight, whereas those in Mali and South Africa did not. The trial
in Nepal did not find an impact on preterm births or SGA overall
but did find a greater birth weight effect during high circulation
of influenza and when there was a match between vaccine strains
and those in circulation [13]. Given the impact of LBW and gesta-
tional age on infant growth, we sought to examine whether the
positive effect of maternal influenza vaccination on birth weight
had longer term advantages for infant growth at 6 months of age
in the trial we undertook in the southern plains of rural Sarlahi dis-
trict, Nepal.
2. Methods
A randomized placebo controlled trial of year round maternal
influenza vaccination versus saline placebo was conducted in
Nepal from April 2011 with follow up through April 2014, when
enrolled women and their infants had been followed through 6
months postpartum. The trial is registered at clinicaltrials.gov
(NCT01034254). Methods are described in detail elsewhere
[11,12]. Briefly, the trial was conducted in 9 Village Development
Committees of Sarlahi district. Data collectors identified house-
holds with women 15–40 years of age and visited them every 5
weeks to ask about menses and provide pregnancy tests for
women who had not menstruated since the last visit. Date of last
menstrual period was recorded at each 5 weekly visit. All pregnant
women in this geographic area were approached to participate in
the trial. They were consented and individually randomized in
blocks of 8, stratified by gestational age at vaccination (17–25
and 26–34 weeks), to influenza vaccine or a saline placebo in two
cohorts. The first cohort was enrolled and vaccinated from April
25, 2011 through April 24, 2012. The second cohort was enrolled
between April 25, 2012 and April 24, 2013, but vaccinations in
cohort 2 were assigned to be administered randomly between 17
and 34 weeks gestation. Hence, vaccinations occurred between
April 25, 2012 and September 9, 2013. Vaccine used was the inac-
tivated trivalent influenza Vaxigrip vaccine (Sanofi Pasteur, Ltd.).
Follow-up of all vaccinated mother-infant dyads through 6 months
post-partum ended April 2014. The intervention was masked to
everyone except those administering the vaccinations. Following
vaccination, women were visited in their homes weekly through
6 months post-partum. At these visits, women were asked to recall
their own respiratory symptoms in the prior week, and following
delivery, of their infant(s). Women with fever and other respiratory
symptoms had a mid-nasal swab collected. Infants with fever or
any other respiratory symptoms were also swabbed. Specimens
were tested for influenza, pertussis and a panel of other respiratory
viruses using RT-PCR [14]. Primary outcomes of the trial were
influenza-like illness in pregnancy, low birth weight, and
laboratory confirmed influenza in infants in the first 6 months of
life. The impact of vaccination on infant nutritional status at 6
months of age was a secondary outcome. However, the trial was
not powered to address the secondary aims. Gestational age was
estimated using prospectively collected dates of last menstrual
period and date of birth.
The sample size of 1850 women in each of the two trial cohorts
was based on detecting a 50% reduction in laboratory confirmed
influenza in infants, a 33% reduction in influenza like illness in
women and a 25% reduction in LBW with an overall type I error
of 5% (0.017 for each of the 3 outcomes) and power of 90% for each
trial cohort separately. The study was powered for the 3 primary
trial outcomes but not for differences of public health importance
in 6 month nutritional status.
As soon after birth as possible, data collectors visited the homes
of newborns to record the outcome of the pregnancy, weigh the
newborn and measure length and head circumference. The same
measurements were taken at 6 months post-partum prior to dis-
charge from the trial. Weights at both times were measured with
a digital infant scale, either the Seca model 727 (measuring to
the nearest 2 g) or the Tanita model BD-585 (measuring to the
nearest 10 g). Scales were standardized daily with standard
weights before use. Length was measured using a Shorr length
board to the nearest 0.1 cm. Three measures were taken and the
median recorded for analysis. Head circumference was measured
using a Kendall mid upper arm circumference tape to the nearest
0.1 cm. The tape was firmly placed around the frontal bones just
superior to the supra-orbital ridges, passed around the head at
the same level on each side, and laid over the maximum occipital
prominence at the back of the head. The median of three measure-
ments was recorded for analysis. Measurements taken within 72 h
of birth were used to estimate birth weight, low birth weight
(<2500 g), birth length, head circumference at birth, and SGA
(infants below the 10th percentile of the Intergrowth International
fetal growth standard) [15]. For 6-month follow up, measures were
used if taken between 150 and 210 days after birth.
Characteristics of infants whose mothers received placebo and
flu vaccine were compared among infants who had anthropometric
measurements at 6 months of age. The same characteristics were
also compared between all live births who did and did not have
6 month anthropometry. Among those with 6 month anthropome-
try, the impact of the vaccine was estimated by calculating the
mean difference and 95% confidence intervals in weight, height
and head circumference between treatment groups. These mea-
sures were not adjusted for infant age because the mean age of
measurement in each group was identical (175 days). The WHO
growth standards were used to calculate length-for-age and
weight-for-length z-scores (ref WHO standards) [16]. These
growth standards are age and sex specific. Any weights and lengths
for which the Z-scores were <7 or 7 or missing (2 infants were
missing sex) were excluded from the analysis. The impact of the
vaccine on stunting (<2 z-scores length for age), severe stunting
(<3 Z-scores), wasting (<2 Z-scores weight for length) and sev-
ere wasting (<3 Z-scores) was compared by calculating risk ratios
and 95% confidence intervals from log-binomial regression models.
These treatment effects were also stratified by LBW, SGA, preterm,
infant influenza, and sex of the infant. We also examined the
impact of LBW and influenza infection in the first six months of life
on growth of infants to assess the extent to which these two factors
associated with vaccine efficacy might contribute to 6-month
growth. Analyses were conducted for each cohort separately and
for the two cohorts combined, as was done in the primary out-
comes paper [12].
To examine the impact of differences between infants who did
and did not have anthropometry at 6 months of age, we imputed
missing lengths and weights as a sensitivity analysis only. The
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following predictor variables were used: age of the child (in days)
at the six-month follow-up visit, birthweight, gestational age at
birth, sex, death within first six months of life, maternal height
(<150 cm vs. 150 cm), primiparity, vaccination status (mother
received influenza vaccine vs. placebo from study), and gestation
in pregnancy at which the vaccine was received. The multiple
imputation command ‘‘mi” in Stata was used to create 20 imputa-
tions which were pooled according to the approach of Rubin [17].
The Z-scores for weight-for-length and length-for-age were also
imputed and then dichotomized into binary variables of <2 vs.
2 Z-scores and <3 vs. 3 Z-scores respectively.
Informed consent was obtained from all participants. This trial
protocol was approved by the Institutional Review Boards of the
Cincinnati Children’s Medical Center, Johns Hopkins Bloomberg
School of Public Health (JHBSPH), Institute of Medicine at Tribhu-
van University, Kathmandu, Nepal, and the Nepal Health Research
Council. IRBs at Seattle Children’s Hospital, the University of Wash-
ington, and GeorgeWashington University granted oversight to the
IRB at JHBSPH. A Data Safety and Monitoring Board reviewed
adverse events throughout the trial but no interim outcome anal-
yses were conducted.
3. Results
A total of 3693 women were randomized to placebo (1846) or
influenza vaccine (1847), resulting in 1826 (placebo) and 1820
(influenza) livebirths (Fig. 1). 8 infants were removed from the
analysis because their mothers received the vaccine within two
weeks of delivery and thus were not expected to have responded
fully to the vaccine. Among live born infants who survived through
180 days of age, feasible lengths and weights were measured
within 150–<120 days of age for 70.7% of placebo and 72.7% of
flu vaccine infants.
Characteristics of infants with anthropometry at six months
were comparable between those whose mothers received placebo
and those who received flu vaccine (Table 1). Among those live
births without 6-month anthropometry, infants of women who
received flu vaccine had birth weights 87 g heavier than those
who received placebo (Supplemental Table 1). In addition, the per-
cent LBW and SGA were lower for infants without anthropometry
whose mothers received flu vaccine compared with placebo
infants. Other characteristics were comparable between treatment
groups for those who did not have 6-month anthropometry. Pla-
cebo infants without anthropometry at 6-months (including 49
infants who died prior to the 6 month follow up visit) had lower
mean birth weights (69 g, p = 0.013), higher% LBW (p = 0.005)
and preterm (p = 0.016), lower % vaccinated earlier in pregnancy
(17–<25 weeks, p < 0.001), and nulliparous (p = 0.025) than pla-
cebo infants measured at 6 months (Table 1 and Supplemental
Table 1). Among infants whose mothers received flu vaccine, the
infants with and without anthropometry were statistically signifi-
cantly comparable although comparisons of some of these charac-
teristics may have been underpowered given the sample size. The
1846 mothers with placebo 
1811 mothers with live birth outcome 
1826 live births 
(1796 singletons, 30 twins) 
3 miscarriages, 1 aboron, 31 sllbirths 
7 vaccinated w/i 2 weeks before 
delivery 
1819 eligible live births 
1565 6-mo visits within 150-210 days in age, 
indicang child as alive 
1272 six-month anthropometry records 
-----
1250 with feasible height / weight 
1257 with feasible head circumference 
*Feasible defined as ≥7 & <-7 Z-scores for length-for-age, weight-for-age, and weight-for-length.   
1847 mothers with flu vaccine 
1810 mothers with live birth outcome 
1820 live births 
(1799 singletons, 21 twins) 
5 miscarriages, 33 sllbirths 
1 vaccinated w/i 2 weeks before 
delivery 
1819 eligible live births 
1559 6-mo visits within 150-210 days in age, 
indicang child as alive 
1282 six-month anthropometry records 
-----
1276 with feasible height / weight 
1273 with feasible head circumference 
- 49 deaths before 6-mo follow up 
- 153 with 6-mo visit before or aer 
150-210 days in age 
-   52 lost to follow up 
-    57 deaths before 6-mo follow up 
- 154 with 6-mo visit before or aer 
150-210 days in age 
- 49 lost to follow up 
286 not met 
2 refused 
5 moved 
275 not met 
1 refused 
1 moved 
Fig. 1. Flow diagram of participation and follow up of infant growth in the randomized controlled trial of maternal influenza vaccination in rural Nepal.
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mean age at which infants had anthropometry taken was 175 days
in both groups.
There were no statistically significant differences in mean
weight or length at six months of age between vaccine and placebo
groups, and no differences between groups when stratified by
LBW, preterm, SGA or trial cohort (Table 2). However, the 95% con-
fidence limits for the difference in mean weight at 6 months of age
were consistent with up to a 65 g lower weight among vaccinated
infants than those receiving placebo and up to a 90 g higher mean
weight among vaccinated infants.
The mean 6 month weights and lengths were plotted by calen-
dar time overlaid onto the intensity of circulation of influenza virus
by strain (Figs. 2a and 2b). The peak season of circulation was
approximately June/July/August each year although a low level of
circulation continued during many other months of the year. In
terms of a match between vaccine protection and circulating virus
strains, only two vaccines were used during the trial. The first con-
tained protection against Perth A/H3N2, California A/H1N1 and B/
Brisbane (Victoria) strains and was used from April 25, 2011
through October 20, 2012. The second contained B/Brisbane Victo-
ria, A/H3N2, California A/H1N1, and B/Wisconsin (Yamagata), and
was used from October 21, 2012 through September 9, 2013. As
can be seen on the figures, B/Wisconsin (Yamagata) circulated from
November 2011 through January 2012 and August through Octo-
ber 2012, which was prior to the switch from the first to the second
vaccine. During that time, the vaccine strain (B/Victoria) did not
antigenically match the circulating strain (B/Yamagata) and good
protection against influenza B was not seen in our study during
those times. Children born to mothers who received flu vaccine
at the start of the influenza season (June/July with 6 month old
Table 1
Baseline characteristics of infants with anthropometry at 6 months of age whose mothers received placebo or flu vaccine.
Placebo (n = 1250) Vaccine (n = 1276)





Birthweight in grams (taken within 72 h) 997 2780 (450) 1032 2806 (450)
Gestational age in weeks (within feasibility range of 23–<50 weeks) 1247 39.4 (2.4) 1274 39.5 (2.4)
LBW 997 24.9 1032 22.9
SGA (Intergrowth)19 955 36.7 982 36.1
Preterm 1247 12.3 1274 11.8
Age when six-month anthropometry taken, in days 1250 175 (10) 1276 175 (10)
Maternal characteristics at time of vaccination
Age (years) 1250 23.1 (4.6) 1276 23.3 (4.7)
Gestational age at vaccination (weeks) 1249 23.2 (5.1) 1276 23.2 (5.3)
<26 65.4 64.6
26 34.6 35.4
Systolic BP, at enrollment (mm Hg) 1244 100.2 (9.7) 1272 100.3 (9.5)
Diastolic BP, at enrollment (mm Hg) 1244 66.4 (8.5) 1272 66.5 (9.1)
Height, at enrollment (cms) 1246 151.8 (5.5) 1272 151.9 (5.5)
Weight, at enrollment (kgs) 1247 48.1 (7.2) 1273 48.7 (7.8)





No education 1181 59.6 1211 58.8
Nulliparous 1247 41.1 1273 40.1
*Includes children who contributed feasible height and weight data, had to be age 150–<210 days when measurement taken.
Table 2
Six-month weights and lengths of live born infants by treatment group and vaccine impact on weights and lengths by birth outcomes and cohorts.
Weight (grams) Length (cms)
N Mean (SD) Mean (SD)
Placebo 1250 6791 (1015) 64.3 (2.5)





Overall effect 12.5 (64.9, 90.0) 0.06 (0.13, 0.25)
LBW* 484 12.4 (142.8, 167.6) 0.38 (0.05, 0.80)
Non-LBW 1545 19.6 (112.9, 73.7) 0.10 (0.32, 0.12)
Preterm 303 63.0 (162.4, 288.5) 0.33 (0.24, 0.91)
Term 2218 0.6 (82.7, 81.5) 0.00 (0.20, 0.21)
SGA* 704 14.2 (151.7, 123.2) 0.02 (0.34, 0.38)
AGA 1233 3.4 (108.6, 101.8) 0.07 (0.19, 0.32)
Cohort 1 1528 5.5 (105.1, 94.1) 0.16 (0.09, 0.41)
Cohort 2 998 41.6 (81.9, 165.0) 0.11 (0.41, 0.19)
* Overall effect includes all infants with 6 month anthropometry but LBW and SGA includes only those with birth weight within 72 h.
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measurements in December/January) did not appear to have
higher weights and lengths than those who mothers received pla-
cebo. Children growing when B/Wisconsin (Yamagata) was circu-
lating and the vaccine did not contain this antigen had similar
attained mean weights and lengths as those growing during peri-
ods when the vaccine contained antigens matching the circulating
virus strains. Mean 6 month weight was 30.3 g (95% CI: 60.3,
120.8) greater in vaccinated versus placebo infants during the per-
iod where the vaccine did not protect against B Yamagata and 29.0
g (95% CI: 26.9, 84.9) greater among vaccinated versus placebo
infants in the time periods where the vaccine did protect against
circulating viruses. Similarly, 6 month length was 0.03 (95% CI:
0.15, 0.20) greater during the period when the vaccine did not
protect against B Yamagata and 0.03 cm (95% CI: 0.13, 0.20) less
in the vaccine compared to placebo during the period when the
vaccine was protective against circulating strains.
There were no statistically significant differences in the propor-
tion stunted or wasted at 6 months between the placebo and vac-
cine groups (Table 3). However, the 95% confidence intervals were
consistent with up to a relative reduction in wasting of 15% and in
stunting of 24%. Maternal influenza vaccine was protective against
severe wasting (RR: 0.69 (0.44, 1.07)) and severe stunting (RR: 0.64
(0.39, 1.04)) although not statistically so. While LBW and preterm
infants whose mothers received flu vaccine had lower severe
stunting than those who received placebo, these differences were
not statistically significant. Among appropriate for gestational
age (AGA) infants, the flu vaccine significantly reduced stunting
(RR: 0.71 (0.51, 0.99)). The impact of flu vaccine on wasting was
greater in cohort 2 than in cohort 1 (cohort 2 also had the larger
birth weight effect), with RR: 0.66 (0.44, 0.99) for any wasting,
and RR: 0.45 (0.19, 1.09) for severe wasting. There were no differ-
ences in vaccine effect on anthropometric outcomes by sex of the
infant, or by whether the infant had laboratory confirmed influ-
enza in the first six months of life (data not shown). Mean head cir-
cumference of placebo and vaccine infants were not different at
birth or at six months of age (32.8 cm at birth and 41.1 cm at six
months in the placebo group and 32.9 cm at birth and 41.2 cm at
six months in the vaccinated group).
In order to examine mechanisms by which poorer growth in the
first six months of life might occur, we compared the attained
mean 6 month weight and length of LBW infants to those of nor-
mal birth weight, adjusted for maternal height, parity, infant sex,
age at first marriage and treatment group. LBW infants attained




























































































































































































Fig. 2a. Mean weight at 6 months of age in grams (left Y axis) for infants born to mothers who received vaccine or placebo in pregnancy by calendar time (X axis) overlaid on

























































































































































































Fig. 2b. Mean length at 6 months of age in centimeters (left Y axis) for infants born to mothers who received vaccine or placebo in pregnancy by calendar time (X axis)
overlaid on incidence of circulating influenza strains (right Y axis).
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786, 609) less than normal birth weight infants (Table 4). LBW
infants also had significantly higher rates of stunting and wasting
at six months compared to normal birth weight infants (Table 5).
Similarly, infants with laboratory confirmed influenza gained less
weight and length but these differences were much smaller than
for LBW and not statistically significant (Tables 4 and 5).
Imputation of missing weights and lengths at 6 months
increased the weights and lengths available from n = 2526 to n =
3197. When the imputed weights, lengths, weight-for-length Z-
scores, and length-for-age Z-scores were used in the regression
analyses, there were no changes in the inferences from the analy-
ses conducted without the imputed values (Supplemental Table 2).
4. Discussion
We have previously shown that influenza vaccine reduced
influenza-like illness in pregnancy, laboratory-confirmed influenza
in infants during the first six months of life in southern Nepal, LBW
by 15%, and modestly increased birth weight [12]. In this analysis
of infant anthropometry at six months of age, there was no evi-
dence of a statistically significant reduction in mild to moderate
stunting or wasting at six months of age. Although the point esti-
mates of the differences between the vaccine and placebo groups
were not of public health importance, the confidence intervals
for these effects were consistent with impacts of importance that
may have been detected with a larger sample size. The vaccine
impact on severe stunting and wasting was larger but these were
meaningful public health differences which we did not have the
power to detect given the sample size and the relatively low preva-
lence of severe stunting and wasting. The vaccine did have a statis-
tically significant 34% reduction in wasting and a 55% reduction in
severe wasting in the 2nd annual cohort. This corresponds with the
larger impact on birth weight in the second cohort of 62 grams as
well as a better vaccine match during part of this time period.
These results are likely generalizable to rural populations of
South Asia among women of low stature and body mass index
(BMI), which may have limited the ability to observe a growth
effect on infants. There was also little evidence that maternal influ-
enza vaccine benefited any subgroups of infants over others. In
particular, infants with adverse birth outcomes such as being born
LBW or preterm were not seen to benefit more or less than those
without these conditions, although the study was not powered to
detect such effect modifications. Although LBW infants had lower
attained weight and length than normal birth weight infants at
6 months of age, the impact of the vaccine on 6 month anthropom-
Table 3
Six-month stunting and wasting among live born infants by treatment group and
vaccine impact on wasting and stunting by birth outcomes and cohorts.
Wasting Stunting
Z-score < 2 N % %
Placebo 1250 10.3 14.8
Vaccine 1276 11.0 13.6
RR (95% CI) RR (95% CI)
1.06 (0.85, 1.33) 0.92 (0.76, 1.12)
LBW 484 1.24 (0.84, 1.83) 0.91 (0.68, 1.21)
Non-LBW 1545 1.04 (0.76, 1.44) 0.92 (0.67, 1.24)
Preterm 303 1.38 (0.77, 2.48) 0.92 (0.62, 1.36)
Term 2218 1.04 (0.81, 1.32) 0.95 (0.76, 1.18)
SGA 704 1.18 (0.84, 1.64) 1.03 (0.77, 1.38)
AGA 1233 1.09 (0.75, 1.58) 0.71 (0.51, 0.99)
Cohort 1 1528 1.34 (1.01, 1.78) 0.82 (0.62, 1.08)
Cohort 2 998 0.66 (0.44, 0.99) 1.06 (0.81, 1.38)
Z-score < 3 N % %
Placebo 1250 3.8 3.2
Vaccine 1276 2.6 2.0
RR (95% CI) RR (95% CI)
0.69 (0.44, 1.07) 0.64 (0.39, 1.04)
LBW 484 1.24 (0.84, 1.83) 0.67 (0.35, 1.28)
Non-LBW 1545 1.04 (0.76, 1.44) 0.71 (0.25, 2.02)
Preterm 303 1.38 (0.77, 2.48) 0.61 (0.23, 1.64)
Term 2218 1.04 (0.81, 1.32) 0.67 (0.38, 1.18)
SGA 704 0.90 (0.51, 1.60) 0.66 (0.32, 1.35)
AGA 1233 0.69 (0.031, 1.54) 0.53 (0.20, 1.41)
Cohort 1 1528 0.79 (0.48, 1.32) 0.62 (0.32, 1.17)
Cohort 2 998 0.45 (0.19, 1.09) 0.67 (0.32, 1.41)
Table 4
Impact of low birth weight and laboratory-confirmed influenza incidence on attained weight and length of infants in the first 6 months of life, adjusted.
Weight (g) Length (cm)
N Mean (SD) Mean (SD)
LBW 481 6188 (869) 62.9 (2.4)
Non-LBW (ref) 1537 6935 (935) 64.7 (2.2)
Adjusted Mean Diff (95% CI) Adjusted Mean Diff (95% CI)
2018 697.9 (786.3, 609.4) 1.59 (1.81, 1.38)
Influenza 125 6681 (943) 64.0 (2.2)
No Influenza (ref) 2389 6802 (996) 64.4 (2.5)
Adjusted Mean Diff (95% CI) Adjusted Mean Diff (95% CI)
2514 92.0 (257.7, 73.8) 0.27 (0.67, 0.14)
*Adjusted for maternal height, parity, infant sex, vaccination status, age at first marriage
Table 5
Impact of low birth weight and laboratory-confirmed influenza incidence on stunting




LBW 481 17.5 28.3
Non-LBW (ref) 1537 8.7 9.6
Adjusted RR (95% CI)* Adjusted RR (95% CI)*
2018 2.06 (1.60, 2.65) 2.88 (2.34, 3.54)
Influenza 125 10.4 20.0
No Influenza (ref) 2389 10.6 14.0
Adjusted RR (95% CI)* Adjusted RR (95% CI)*
2514 0.91 (0.54, 1.55) 1.30 (0.92, 1.86)
z-score < 3
LBW 481 5.8 7.5
Non-LBW (ref) 1537 2.7 0.9
Adjusted RR (95% CI)* Adjusted RR (95% CI)*
2018 2.15 (1.33, 3.46) 8.05 (4.47, 14.50)
Influenza 125 4.0 4.8
No Influenza (ref) 2389 3.1 2.5
Adjusted RR (95% CI)* Adjusted RR (95% CI)*
2514 1.12 (0.46, 2.74) 1.67 (0.76, 3.66)
* Adjusted for maternal height, parity, infant sex, vaccination status, age at first
marriage.
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etry did not differ by whether the infant was born LBW or normal
birth weight.
Among infants with 6-month anthropometric measurements,
treatment groups were comparable with regard to birth outcomes
and maternal characteristics that might predict nutritional status
at six months of age. Overall, 28% of trial infants were missing
anthropometry at the six-month visit. Infants in the vaccine group
without 6-month data were comparable to those with anthropom-
etry at six months of age. Infants in the placebo group who did not
have six-month visits were found to have somewhat poorer birth
outcomes than those who had six-month follow-up. Using multiple
imputation of missing 6 month weights and lengths, the poorer
birth outcomes and maternal characteristics did not appear to
change the inferences about treatment effect on nutritional status
at 6 months. However, it is possible that the multiple imputation
did not include some relevant variables that may have identified
biases in the vaccine impact on 6 month anthropometry if
included.
Maternal influenza or influenza-like illness during pregnancy
may increase inflammation and reduce appetite, leading to lower
weight gain in pregnancy, poorer intrauterine growth, LBW, and
possibly preterm delivery [2,18]. In our trial, the impact of vaccina-
tion on low birth weight was a 15% reduction in both cohorts over
the three years of the trial, but with a higher difference in mean
birth weight of 62 grams in the second cohort, possibly associated
with better match between vaccine and circulating virus types
[16]. There was no impact of the vaccine on preterm or gestational
age. The greatest impact of vaccination on birth weight occurred
among infants who were both SGA and preterm [13]. Reductions
in more severe wasting and stunting at 6 months were consistent
with the vaccine’s impact on birth weight and LBW, especially in
the 2nd annual cohort, but the sample size and prevalence of severe
wasting and stunting limited our ability to detect these differences
statistically. Mechanisms by which maternal vaccination might
improve infant growth during the first 6 months of life include
improved birth weight leading to improved postnatal growth
and/or fewer infections in general, or a direct effect of fewer influ-
enza infections early in life. However, influenza is relatively
uncommon in young infants in this area of Nepal (5.8% attack rate
among those in the placebo group) and the vaccine averted only 56
cases of influenza per 1000 child-years. Hence, at a population-
level, such an impact is unlikely to translate into a growth effect,
although our data suggest it may at the more extreme end of the
malnutrition spectrum. Other mechanisms could be postulated
such as the potential impact of fever and increased cytokine
release resulting in inflammatory cascades.
Although this study did not find a statistically significant impact
of the vaccine on infant stunting and wasting at 6 months of age,
the limits of confidence intervals were consistent with impacts of
public health importance, indicating inadequate sample size to
refute the hypothesis of no effect. In addition, sizeable point esti-
mates of the vaccine effect were seen for severe wasting and stunt-
ing, but the study was underpowered to detect these differences.
Another limitation is that although 6 month anthropometry was
obtained in 70% of infants overall, 28% of infants for whom anthro-
pometry was not obtained at six months of age had poorer birth
outcomes in the placebo group relative to those with six month fol-
low up. This could have led to some bias in our vaccine effect esti-
mates. Multiple imputation of the missing 6 month anthropometry
did not indicate such a bias but this analysis is limited by the avail-
ability of predictive variables for such imputation. Strengths of this
study include a large population-based sample of infants enrolled
in a randomized, placebo controlled trial, weight measurements
taken with accurate scales, and the median of three length and
head circumference measurements used in analysis.
The data from this randomized placebo controlled trial suggest
that while maternal influenza vaccination did improve birth
weight and reduce infant influenza infections, these effects were
not large enough to translate into an impact on mild to moderate
malnutrition of the population through six months of life, although
there was some evidence it reduced severe malnutrition, especially
during time periods where the vaccine provided protection against
circulating strains. Given a lack of randomized trial data of the
impact of maternal vaccination on infant growth and the sample
size limitations of this trial, further studies designed to address
malnutrition in young infants as a primary outcome are needed.
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